对以下内容的更正：加卡尼单抗治疗发作性偏头痛：3期研究（EVOLVE-1和EVOLVE-2）中偏头痛发作高频率与低频率的疗效亚组分析。
Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
作者信息
Silberstein Stephen D, Stauffer Virginia L, Day Katie A, Lipsius Sarah, Wilson Maria-Carmen
机构信息
Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.
出版信息
J Headache Pain. 2019 Dec 27;20(1):118. doi: 10.1186/s10194-019-1069-x.
After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.
我们的文章[1]发表后，我们收到通知，图7上排所示数据无意中是第6个月时相对于基线的最小二乘均值变化（标准误差），而非第3个月和第6个月的总体平均值。图注以及文中对数据的讨论过去和现在都是正确的。错误仅存在于图7的上排。图7的图注无需修订。
Zotero 插件